Akba stock forecast
Mar 19, 2020 · AKBA shares had a relatively better volume day versus average trading capacity of 1.5 million shares, but with a 0.11 billion float and a -40.92% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for AKBA stock indicates that the average analyst price target is $15.04 per share. Akebia Therapeutics Inc. (AKBA) is attracting new ... Analyst recommendations provided by FactSet shows that the consensus forecast for Akebia Therapeutics Inc. (AKBA) is a “Overweight”. 8 analysts offering their recommendations for the stock have an average rating of 2.10, where 2 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 0 NASDAQ:AKBA Akebia Therapeutics, Inc. Stock Analysis ... Akebia Therapeutics, Inc. is a biopharmaceutical company, which focuses on development of novel, proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with kidney disease. The Odds of Success for Akebia Therapeutics, Inc. (AKBA) Stock Mar 24, 2020 · Akebia Therapeutics, Inc. (NASDAQ:AKBA) increased by 6.68%, which means its valuation on the stock-market now stands at $599.76M. Its share price closed at $6.23, having traded in a downtrend to hit $5.69. However, it rallied to a high of $6.44 in intraday trading on Monday.
TNXP Stock Analysis: Price, Forecast, and News
AKBA - Akebia Therapeutics Stock Price - Barchart.com 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Why Akebia Therapeutics, Inc. (AKBA) Is Exploding 14.15% ... Mar 19, 2020 · AKBA shares had a relatively better volume day versus average trading capacity of 1.5 million shares, but with a 0.11 billion float and a -40.92% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for AKBA stock indicates that the average analyst price target is $15.04 per share. Akebia Therapeutics Inc. (AKBA) is attracting new ... Analyst recommendations provided by FactSet shows that the consensus forecast for Akebia Therapeutics Inc. (AKBA) is a “Overweight”. 8 analysts offering their recommendations for the stock have an average rating of 2.10, where 2 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 0
Stock Price Forecast for AKBA: Akebia Therapeutics holds several negative signals and is within a very wide and falling trend, so we believe it will still perform
Akebia Therapeutics Stock Price Forecast, AKBA stock price prediction. The best long-term & short-term Akebia Therapeutics share price prognosis for 2020, Find the latest Akebia Therapeutics, Inc. (AKBA) stock quote, history, news and other vital information to help you with your stock trading and investing. AKBA investment & stock information. Get the latest Akebia Therapeutics, Inc. AKBA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Real time Akebia Therapeutics (AKBA) stock price quote, stock graph, news & analysis. 5 brokers rate it as a 'Buy'. Click to view NMQ:AKBA's StockReport. Momentum · StockRank™ · StockReport™. Tools 12m Forecast Rolling, Industry, Market Average weighted alpha of all stocks in this sector: 52 WK High 52 WK Low. Other Sectors containing Akebia Therapeutics (AKBA). SIC-2834 Pharmaceutical Nov 27, 2019 For investors seeking out the ultimate high-risk, high-reward stocks, look to no “ holds” or “sells,” the consensus is unanimous: AKBA is a “strong buy.” In addition, the $16 average price target indicates 218% upside potential.
Real time Akebia Therapeutics (AKBA) stock price quote, stock graph, news & analysis.
AKBA / Akebia Therapeutics, Inc. 424B5 - Prospectus - 424B5. 03-12 sec.gov 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-223585 CALCULATION OF REGISTRATION FEE Title of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, $0.00001 par value per share $65,000,000 $8,437 (1) The filing fee of $8,437 is AGEN Agenus Inc. — Stock Price and Discussion | Stocktwits Apr 03, 2020 · Securities products and services offered to self-directed investors through ST Invest, LLC. Member FINRA / SIPC.ST Invest is a wholly owned subsidiary of StockTwits, Inc. Investing in securities products involves risk, including possible loss of principal. Please read important legal disclosures.
Get your free Akebia Therapeutics Inc stock live and up-to-date data - AKBA Quote, charts, rates, analysis, news & forecasts. Enter Now!
Jan 11, 2019 · The current bear market offers many high-quality companies that are on sales at a deep bargain. As we continue our bargain-hunting quest, we stumbled upon Akebia Therapeutics. 5 “Strong Buy” Biotech Stocks With More Than 80% Upside Nov 27, 2019 · See the AKBA stock analysis. Aerie Pharmaceuticals (AERI) While Bernardino’s forecast implies huge upside potential, based on the $23 average price target the Street sees even more. We’re Akebia Therapeutics Stock Forecast | AKBA Stock Predictions See AKBA stock predictions by 2 financial experts and find out if their Akebia Therapeutics stock forecast (AKBA) is more bullish in comparison to other stocks in the Healthcare sector. 5 “Strong Buy” Biotech Stocks With More Than 80% Upside
View Abeona Therapeutics Inc. ABEO investment & stock information. Get the latest Abeona Therapeutics Inc. ABEO detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. AKBA - Akebia Therapeutics Stock Price - Barchart.com 60-Month Beta: Coefficient that measures the volatility of a stock's returns relative to the market (S&P 500). It is based on a 60-month historical regression of the return on the stock onto the return on the S&P 500. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. Why Akebia Therapeutics, Inc. (AKBA) Is Exploding 14.15% ... Mar 19, 2020 · AKBA shares had a relatively better volume day versus average trading capacity of 1.5 million shares, but with a 0.11 billion float and a -40.92% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for AKBA stock indicates that the average analyst price target is $15.04 per share. Akebia Therapeutics Inc. (AKBA) is attracting new ... Analyst recommendations provided by FactSet shows that the consensus forecast for Akebia Therapeutics Inc. (AKBA) is a “Overweight”. 8 analysts offering their recommendations for the stock have an average rating of 2.10, where 2 rate it as a Hold and 0 think it is a “Overweight”. 6 of the analysts rate the stock as a “Buy”. 0